Overview

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Status:
Recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

Phase:

Phase 2

Details

Lead Sponsor:

Center for International Blood and Marrow Transplant Research

Collaborator:

National Marrow Donor Program

Treatments:

Busulfan
Cyclophosphamide
Fludarabine
Melphalan
Mycophenolic Acid
Tacrolimus